IL6 and Fabry disease: Biancini et al. (14), using a multi-analyte panel similar to that presented herein, evaluated 14 FD patients being treated with ERT and found elevated plasma levels of IL-6 and TNF-α compared to those in controls, and also advocated for the role of Gb3 as a promoter of inflammation.